XORTX Therapeutics (XRTX) Free Cash Flow (2022 - 2023)

XORTX Therapeutics' (XRTX) quarterly Free Cash Flow came in at -$13.9 million in Q4 2022, down 1557.19% on a QoQ basis from $951980.6 in Q3 2022.

XORTX Therapeutics (XRTX) Free Cash Flow (2022 - 2023) Analysis & Trends

XORTX Therapeutics (XRTX) has 1 years of Free Cash Flow data on file, last reported at -$13.9 million in Q4 2022.

Quarterly Free Cash Flow changed N/A year-over-year to -$13.9 million in Q4 2022, while the trailing twelve-month figure through Sep 2023 was -$13.9 million (down 1557.19% YoY) and the FY2025 annual result came in at -$2.8 million, up 24.74% from the prior year.
Free Cash Flow declined to -$13.9 million in Q4 2022, from $951980.6 in the prior quarter.
In the past five years, Free Cash Flow ranged from a high of $951980.6 in Q3 2022 to a low of -$13.9 million in Q4 2022.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)	Free Cash Flow (Qtr)
1	Vertex Pharmaceuticals	139.13 Bn	131.28 Bn	2.84 Bn	1.01 Bn
2	Regeneron Pharmaceuticals	85.77 Bn	77.77 Bn	3.93 Bn	572.80 Mn
3	Argenx Se	64.64 Bn	59.46 Bn	1.37 Bn	-
4	Moderna	58.29 Bn	53.16 Bn	52.00 Mn	-563.00 Mn
5	BeOne Medicines	41.92 Bn	36.82 Bn	1.53 Bn	437.80 Mn
6	Alnylam Pharmaceuticals	31.58 Bn	28.28 Bn	992.69 Mn	292.04 Mn
7	BioNTech SE	28.12 Bn	9.73 Bn	668.28 Mn	433.84 Mn
8	Insmed	27.39 Bn	26.22 Bn	358.27 Mn	-95.09 Mn
9	Royalty Pharma	27.27 Bn	26.43 Bn	-	477.44 Mn
10	XORTX Therapeutics	2.84 Mn	2.84 Mn	-	-

Download Data